Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GIANCARLO MOSCOL

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1508094392
CMS profile
159159
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$8,734.71

35 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,350.00 8
Food and Beverage $1,286.53 15
Long term medical supply or device loan $1,098.18 12

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $5,146.82 11
Novartis Pharmaceuticals Corporation $1,361.75 15
BeiGene USA, Inc. $620.00 1
Halozyme Inc $610.00 1
TerSera Therapeutics LLC $540.00 1
Gilead Sciences, Inc. $394.07 5
PUMA BIOTECHNOLOGY, INC. $62.07 1

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

35 matching records · $8,734.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 35 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–35 of 35.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $525.0012/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/20261104347416 CMS
Novartis Pharmaceuticals Corporation $125.7912/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094382 CMS
AstraZeneca Pharmaceuticals LP $125.0012/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261104599210 CMS
Novartis Pharmaceuticals Corporation $83.3312/10/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094380 CMS
AstraZeneca Pharmaceuticals LP $1,340.0011/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/20261104564970 CMS
Novartis Pharmaceuticals Corporation $83.3311/14/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094362 CMS
Novartis Pharmaceuticals Corporation $83.3310/17/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094364 CMS
Novartis Pharmaceuticals Corporation $83.3309/27/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094336 CMS
Novartis Pharmaceuticals Corporation $35.3109/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261086966822 CMS
Gilead Sciences, Inc. $21.2709/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261133832622 CMS
Gilead Sciences, Inc. $48.9609/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261133832620 CMS
Novartis Pharmaceuticals Corporation $83.3308/23/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094334 CMS
AstraZeneca Pharmaceuticals LP $22.1008/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261104282477 CMS
AstraZeneca Pharmaceuticals LP $105.9708/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261105505748 CMS
AstraZeneca Pharmaceuticals LP $119.3008/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261105546657 CMS
AstraZeneca Pharmaceuticals LP $76.1608/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261105568787 CMS
Novartis Pharmaceuticals Corporation $83.3307/15/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094350 CMS
PUMA BIOTECHNOLOGY, INC. $62.0707/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261113854603 CMS
AstraZeneca Pharmaceuticals LP $525.0006/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/20261104293714 CMS
Novartis Pharmaceuticals Corporation $102.4706/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094306 CMS
Novartis Pharmaceuticals Corporation $99.7006/13/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094348 CMS
Gilead Sciences, Inc. $80.7706/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261133832618 CMS
Gilead Sciences, Inc. $130.2106/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261133832616 CMS
BeiGene USA, Inc. $620.0005/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/20261120864004 CMS
Gilead Sciences, Inc. $112.8605/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261133832614 CMS
AstraZeneca Pharmaceuticals LP $1,665.0005/20/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/20261105560686 CMS
Novartis Pharmaceuticals Corporation $99.7005/16/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094346 CMS
Novartis Pharmaceuticals Corporation $99.7004/18/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094344 CMS
TerSera Therapeutics LLC $540.0004/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/20261144714565 CMS
Novartis Pharmaceuticals Corporation $99.7003/15/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094342 CMS
AstraZeneca Pharmaceuticals LP $525.0003/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/20261105506252 CMS
Novartis Pharmaceuticals Corporation $99.7002/16/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094340 CMS
AstraZeneca Pharmaceuticals LP $118.2902/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/20261105746571 CMS
Novartis Pharmaceuticals Corporation $99.7001/18/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/20261087094338 CMS
Halozyme Inc $610.0001/02/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/20261146487064 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,266.30 13
PY2020 $8,759.21 8
PY2021 $6,729.69 16
PY2022 $6,818.90 11
PY2023 $11,962.28 28
PY2024 $8,734.71 35
PY2025 $20,496.16 44

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Cite this record.

Plain
GIANCARLO MOSCOL, NPI 1508094392. IndustryPayments, data edition 2026-07-26T04:22:22Z. https://industrypayments.org/provider/npi-1508094392.
APA 7
IndustryPayments. (2026). GIANCARLO MOSCOL, NPI 1508094392 (Data edition 2026-07-26T04:22:22Z) [Data set]. https://industrypayments.org/provider/npi-1508094392
Bluebook
GIANCARLO MOSCOL, NPI 1508094392, IndustryPayments (data edition 2026-07-26T04:22:22Z), https://industrypayments.org/provider/npi-1508094392.

Source: Centers for Medicare & Medicaid Services, Open Payments.